Benchmark Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman reiterates a Buy rating on Halozyme Therapeutics (NASDAQ:HALO) and maintains a $50 price target.

April 16, 2024 | 1:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman reiterates a Buy rating on Halozyme Therapeutics with a $50 price target.
The reiteration of a Buy rating and maintenance of a $50 price target by a Benchmark analyst suggests a positive outlook for Halozyme Therapeutics. This endorsement likely signals confidence in the company's future performance, which could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100